OBJECTIVES: Ultra orphan therapies are indicated for rare diseases affecting less than a few thousand patients. The annual and lifetime per patient cost of these treatments have generated controversy and policy questions regarding cost effectiveness and reimbursement. The objective of this analysis was to review all available cost effectiveness studies and develop lessons for policy development for ultra orphan therapies. METHODS: